bioMerieux SA · EURONEXT:BIM
bioMerieux SA — H1 2021 Earnings Presentation
18 slides from bioMerieux SA's earnings presentation, Sep 1, 2021
Slide 1: H1 2021 Results & Outlook
H1 2021 Results & Outlook September 1st, 2021 PIONEERING DIAGNOSTICS
Slide 2: Disclaimer
DISCLAIMER • This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMéri
Slide 3: Agenda
AGENDA OVERVIEW of bioMérieux H1 2021 ACTIVITY REVIEW H1 2021 FINANCIAL RESULTS 2021 OUTLOOK BIOMÉRIEUX BIOMÉRIEUX
Slide 4: Key Takeaways – H1 2021 Performance
KEY TAKEAWAYS – H1 2021 PERFORMANCE SALES PROFITABILITY BUSINESS TRENDS €1,574m €374m Molecular biology +12.3% 23.8% of sales at constant exchange rates and scope of consolidation vs. 17.1% in H1 2020 Microbiology Immunoassays FREE CASH FLOW LEVERAGE €145m 0.1x EBITDA Industry BIOMÉRIEUX
Slide 5: BIOFIRE Leading Multiplexing Testing
BIOFIRE® LEADING MULTIPLEXING TESTING BIOFIRE® Panels Sales +79% • Key Growth drivers: Key Syndromic breakdown Respiratory: Japan & Northen EU Diagnostic solution Respiratory Other panels: US & Europe Installed base Other panels • Joint Infections panel under FDA review @ 20,100 units X2 in 18 m
Slide 6: 2021 H1: A Rich Portfolio of Product Launches
2021 H1: A RICH PORTFOLIO OF PRODUCT LAUNCHES MICROBIOLOGY SPECIFIC REVEAL VITEK MS Rapid-AST PRIME Co-Distribution MOLECULAR / Sequencing De Novo Respiratory 2.1 EPISEQ BIOFIRE SARS-COV-2 IMMUNOASSAY SARS-COV-2 II semi NEPHROCHECK TB IGRA Dengue quantitative VIDAS VIDAS VIDAS VIDAS Jan. Feb. Mar. A
Slide 7: Solid Growth in Clinical Microbiology
SOLID GROWTH IN CLINICAL MICROBIOLOGY Newly launched VITEK MS +13% ORGANIC SALES PRIME GROWTH • Growing vs pre-pandemic levels • Performance led by automated ID/AST and Blood Culture, particularly in North America & ASPAC • Good progress on Vitek MS Prime controlled launch • Co-exclusive distributio
Slide 8: Strong Momentum in Other Ranges
STRONG MOMENTUM IN OTHER RANGES IMMUNOASSAYS INDUSTRY APPLICATIONS +29% +17% ORGANIC SALES ORGANIC SALES GROWTH GROWTH • Growth fueled by both COVID-19 related • Recovery confirmed in all regions. Strong parameters and routine testing Equipment installations in Q1 and Q2. Reagents sales back to robu
Slide 9: Agenda
AGENDA OVERVIEW of bioMérieux H1 2021 ACTIVITY REVIEW H1 2021 FINANCIAL RESULTS 2021 OUTLOOK BIOMÉRIEUX BIOMÉRIEUX
Slide 10: H1 2021 Sales by Application
H1 2021 SALES BY APPLICATION: Solid performance of microbiology, immunoassays & industry €54m 3% €538m 34% INDUSTRY +17% MOLECULAR +3% €244m 16% GROUP €1,574m +12.3% €241m 15% €496m IMMUNOASSAYS +29% 32% MICROBIOLOGY +13% Clinical applications (84%) +12% MICROBIOLOGY +13% BIOMÉRIEUX
Slide 11: BIOFIRE Growing IB & Non RP Panels in H1
BIOFIRE® GROWING IB & NON RP PANELS IN H1 Installed base • First Semester increase: 60% US / 40% OUS 20 100 80% Sold / 20% Placed 17 300 10 400 • In the US, ~40% of H1 installations were to new customers Dec. 2019 Dec. 2020 Jun. 2021 BIOFIRE® Respiratory panels in US After slowing down at end of
Slide 12: H1 2021 Sales by Geography
H1 2021 SALES BY GEOGRAPHY: Strong momentum in EMEA & ASPAC HY 2021 REVENUES €1,574m AMERICAS EMEA ASPAC €732m €549m €293m 46% of sales 35% of sales 19% of sales ORGANIC GROWTH +5% +18% +25% +12.3% BIOMÉRIEUX
Slide 13: H1 2021 Sales
H1 2021 SALES Currency Change in scope of Organic effect consolidation growth + € 182m - € 84m €1,574m €1,476m - €0m 0m USD (1) - €62m LatAm (2) - €9m +12.3% Asia (3) - €8m Metera (4) - €5m HY 2020 + 6.6% HY 2021 (1) Including HKD (2) ARS, BRL, CLP, COP, MXN (3) JPI, INR, CNY, KRW, SGD, THB (4) TRY,
Slide 14: H1 2021 P&L: Contributive Operating Income up 59% like-for-like
H1 2021 P&L: Contributive Operating Income up 59% like-for-like In €m H1 As a % H1 As a % % change % change of sales of sales as reported at constant 2021 2020 exchange rates and scope Net sales 1,574 100% 1,476 100% + 6.6% + 12.3% Cost of sales -659 - 41.9% -660 -44.7% - 0.1% + 4.8% Gross profit 91
Slide 15: H1 2021 Cash Flow Statement
H1 2021 CASH FLOW STATEMENT Inventory: - €57m In €m H1 2021 H1 2020 Payables: - €11m EBITDA (1) 471 345 Receivables: +€62m Social & tax debts: - €64m Working capital requirement - 86 - 22 Others: - €17m Income tax paid & financial charges - 102 - 68 Other cash flow from operations 6 18 Capex 9% of S
Slide 16: Agenda
AGENDA OVERVIEW of bioMérieux H1 2021 ACTIVITY REVIEW H1 2021 FINANCIAL RESULTS 2021 OUTLOOK BIOMÉRIEUX BIOMÉRIEUX 17
Slide 17: 2021 Outlook
2021 OUTLOOK Neutral to mid-single digit growth rate Evolving business & pandemic environment Revenues at constant exchange rates Full-year FX impact estimated in line with H1 impact & scope of consolidation Contributive Estimated €30-35m of negative FOREX impacts operating income In lin
Slide 18: Pioneering Diagnostics
BIOMERIEUX PIONEERING DIAGNOSTICS